Summary of Consolidated Financial Results [ IFRS ]for the First Three Months of the Fiscal Year Ending March 31, 2025
August 6, 2024
Listed company name
Code
Listed stock exchanges
URL
Company representative
Contact

:
:
:
:
:
:

Phone
Scheduled date for dividend payment
Preparation of supplementary material forquarterly earnings
Holding of earnings announcement:::

Sysmex Corporation
6869
Tokyo Stock Exchange
www.sysmex.co.jp/en
Kaoru Asano, President
Takuro Minami, Executive Vice President ofCorporate Business Administration
078(265)-0500
―
Yes

:

Yes
(Unit: Millions of Yen)

1. Results for the First Three Months of the Fiscal Year Ending March 31, 2025
(1) Operating results(% changes as compared with the corresponding period of the previous fiscal year)
Net Sales
Three months
ended Jun. 30, 2024
Three months
ended Jun. 30, 2023

Operating profit

Profit before tax

Profit111,946

17.4%

16,743

26.1%

16,97929.0%

10,98428.3%

95,351

10.8%

13,27720.1%

13,160

2.4%

8,561

7.1%

Three months ended Jun. 30, 2024
Three months ended Jun. 30, 2023

Profitattributable toowners of theparent11,031
28.0%
8,621
7.4%

Total
comprehensive
income24,61822,790

8.0%
4.4%

Basic earnings
per share (Yen)

Diluted earnings
per share (Yen)

17.69
13.73

17.69
13.72

Note: The Company conducted a three-for-one stock split on common stock with an effective date of April
1, 2024. Basic earnings per share and diluted earnings per share have been calculated as if the stock
split had taken place at the beginning of the previous consolidated fiscal year.
(2) Financial condition
Total assets
As of Jun. 30, 2024
As of Mar. 31, 2024

Total equity
626,249
618,920

448,784
432,897

Equity attributableto owners of theparent
447,979
432,045

Equity attributableto owners of theparent to total assets
71.5
69.8

2. Dividend
Dividend per shareFirst quarter(Yen)
Year ended Mar. 31, 2024￣

Year ending Mar. 31, 2025￣

Second quarter(Yen)

Third quarter
(Yen)

42.00

Year ending Mar. 31, 2025
(Forecast)Year-end
(Yen)
￣

15.00

￣

Annual
(Yen)
42.00

84.00

15.00

30.00

Notes:
1. Revision of dividends forecast for this period: No
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1,
2024. However, actual dividend amounts prior to this stock split are shown for the fiscal years ended
March 31, 2024.
3. Financial Forecast for the Year Ending March 31, 2025(% changes as compared with the corresponding period of the previous fiscal year)
Net Sales
Six months
ending Sep.
30, 2024
Year ending
Mar. 31, 2025

Operating profit

Profit before tax

Profit attributable toowners of the parent

Basic earnings
per share (Yen)

237,000

11.4%

37,0009.4%

34,9004.8%

23,000

3.7%

36.89

510,000

10.5%

87,00011.0%

82,50010.6%

55,000

10.8%

88.21

Note: Revision of financial forecast for this period: No
4. Other Information(1) Significant changes in scope of consolidation:
No(2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS: No
2) Other changes in accounting policies: No
3) Changes in accounting estimates: No(3) Number of outstanding stock (common stock)1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,371,116 shares as of Jun. 30, 2024; 629,371,116 shares as of Mar. 31, 2024
2) Number of treasury stock at the end of each fiscal period:
5,873,240 shares as of Jun. 30, 2024; 5,872,332 shares as of Mar. 31, 2024
3) Average number of outstanding stock for each period (cumulative):
623,498,103 shares for the three months ended Jun. 30, 2024
627,800,607 shares for the three months ended Jun. 30, 2023
Notes:
1. The Company has introduced Stock-Granting Employee Stock Ownership Plan (ESOP) Trust.
Company shares held by the trust are included in treasury stock and are excluded from calculationsof the number of treasury stock at the end of the fiscal period and the average number ofoutstanding stock for the period.
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1,
2024. The number of outstanding stock at the end of the fiscal period, the number of treasury stockat the end of the fiscal period, and the average number of outstanding stock for the period are
calculated as if the stock split had taken place at the beginning of the previous consolidated fiscalyear.

* Review of the accompanying quarterly consolidated financial statements by a certified public
accountant or auditing firm: Yes (optional)* Explanation regarding the appropriate use of financial forecast and other information
1. Basic earnings per share have been revised from the figures indicated in the consolidated financial
forecast announced on May 9, 2024, in accordance with changes in the number of shares ofoutstanding stock and treasury stock. No other figures in the financial forecast have been revised.
2. The forecasts and future projections contained herein have been prepared on the basis of rational
decisions given the information available as of the date of announcement of this document. These
forecasts do not represent a commitment by the Company, and actual performance may differ
substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial
forecast” within “1. Qualitative information on quarterly financial results” on page 5 of theattachment to this document for cautionary statements concerning the conditions and performance
forecasts that serve as the basis for these forecasts.
3. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website
on Tuesday, August 6, 2024.

Content of Supplementary Materials
1. Qualitative information on quarterly financial results

21) Operating performance analysis

22) Financial conditions analysis

43) Consolidated financial forecast

54) Operating risks

55) Business and financial issues to be addressed56) Important management contracts, etc.

5

2. Condensed quarterly consolidated financial statements and notes

61) Condensed quarterly consolidated statement of financial position

62) Condensed quarterly consolidated statement of income

83) Condensed quarterly consolidated statement of comprehensive income

94) Condensed quarterly consolidated statement of changes in equity

105) Condensed quarterly consolidated statement of cash flows

116) Notes to the condensed quarterly consolidated financial statements

12

1. Key considerations on the basis for the preparation of condensed quarterly consolidated
financial statements
2. Notes related to the going concern assumption

12

3. Segment information

12

- 1 -

12

1. Qualitative information on quarterly financial results1) Operating performance analysis
Future-related information contained in the text below is based on the judgement as of the end of
the fiscal period under review.
In the first quarter of the fiscal year ending March 31, 2025, the outlook for the global economy isbeing adversely affected by both short-term factors, such as high borrowing costs and thewithdrawal of fiscal support, and long-term factors, including Russia's invasion of Ukraine, weak
productivity growth, and worsening geoeconomic fragmentation. However, we expect growth tocontinue at a pace similar to fiscal 2023, driven by aggressive government spending and household
consumption, as well as an expansion of supply capacity, mainly due to an increase in labor market
participation.
On the healthcare front, as global society ages we expect to see efforts to optimize social security
expenditures and decentralize healthcare functions. Against this backdrop, prevention and selfmedication will become increasingly important. At the same time, healthcare disparities and theissue of accessibility to healthcare will continue to persist. Furthermore, we anticipate
advancements in technological innovation such as gene analysis, ultrahigh sensitive measurement,
and miniaturization, which will be applied to healthcare. Demand for personalized medicine will
grow, and we expect the practical application of new treatment methods such as regenerative andcellular medicine and genomic medicine. Additionally, we predict the widespread adoption of
artificial intelligence (AI) and the acceleration of digital transformation (DX) in the healthcare
sector, including the implementation and expansion of robotic technologies. We anticipate further
growth opportunities as a result.
Against this backdrop, we began sales of our own brand of hemostasis testing solutions in the
United States and EU countries*1, based on a mutual OEM supply initiative with Siemens
Healthcare Diagnostics Inc.
in April 2024. This distribution is based on a global OEM agreement
on hemostasis products concluded in February 2023. Moving forward, we will gradually expand theimplementation of sales through this initiative on a global scale. This will enable Sysmex toprovide even more effective solutions under our own brand by combining our strengths with theworld’s leading hemostasis product portfolios. Starting with the United States and EU countries,
which have been vital areas of expansion in our hemostasis field, Sysmex will progressively extend
this new initiative to other countries and regions.
Also, our subsidiary, Sysmex Astrego AB, was awarded one of the UK's biggest science prizes, the“Longitude Prize on AMR,” for the development of the PA-100 AST System, a rapid antimicrobial
susceptibility testing system. The prize is designed to reward and support teams of innovators who
have undertaken the challenge of transforming the conventional clinical workflows for infectious
diseases, thereby making greatest contribution to tackling the global issue of antimicrobial
resistance (AMR)*2. Since the prize launched in November 2014, more than 250 teams from aroundthe world have applied, with Sysmex Astrego AB standing out as the sole recipient. The Longitude
Prize on AMR will serve as a catalyst for Sysmex to further accelerate its efforts in expanding the
global market and its application coverage of the PA-100 AST System, which is set to revolutionize
conventional clinical workflows for infectious diseases. Through this testing system, Sysmex willcontinue its contribution to tackling the universal threat of AMR.
Finally, we launched the HISCL™ VEGF*3 Assay Kit for Research Use and HISCL™ PEDF*4
Assay Kit for Research Use, research reagents for measuring secreted proteins in cell culture media
in regenerative cellular medicine, in Japan, starting from June 20, 2024. A challenge in regenerative
cellular medicine is that the manufacturing cost is higher than that of common small-moleculedrugs. It has been reported that labor costs, including staff-hours, for quality-control testing accountfor approximately 70% of the manufacturing cost of cellular drugs. In addition, since cultured cells
themselves are the raw material for cellular therapeutics, they must be non-destructively inspected
and monitored in quality control testing. Currently, however, such an inspection is performed
manually, and its automation is a challenge. In combination with the Automated Immunoassay
System HISCL™-5000/HISCL™-800, these assay kits can automatically measure secreted proteins,which are indicators of the engraftment ability and functional expression of transplanted cells, in- 2 -just 17 minutes. This can make a significant contribution to greater efficiency and standardizationof work in quality control testing of cellular medicine.
*1 EU countries: Countries including EU member states, Iceland, Liechtenstein, and Norway*2 Antimicrobial resistance (AMR): This phenomenon occurs when living organisms develop a
resistance to a drug, whose efficacy is reduced or nullified as a result. Bacteria that havedeveloped microbial resistance are known as antimicrobial-resistant bacteria. If drugresistant bacteria proliferate, antimicrobials will become less effective, making it difficult totreat infections that would otherwise be mild and reversible.
*3 VEGF (vascular endothelial growth factor): A group of glycoproteins involved in
vascularization (the formation of new blood vessels in areas with no blood vessels during
embryogenesis) and angiogenesis (the formation of blood vessels by branching and elongatingfrom existing vessels).
*4 PEDF (pigment epithelium derived factor): A multifunctional secreted protein with antiangiogenic, anti-tumorigenic, and neurotrophic functions.
Net sales by destination
Three months ended
Three months ended
June 30, 2023
June 30, 2024
Percentage
ofPercentage ofAmountAmount(Millions of yen)
(Millions of yen)
total (%)
total (%)
Japan

YoY
(Previous
period = 100)

13,036

13.7

13,717

12.3

105.2

Americas27,021

28.3

31,638

28.3

117.1

EMEA

28,77530.1

34,726

31.0

120.7

China

16,722

17.6

19,522

17.4

116.7

Asia Pacific

9,795

10.3

12,340

11.0

126.0

Overseas subtotal

82,315

86.3

98,228

87.7

119.3

Total

95,351

100.0

111,946

100.0

117.4

In Japan, sales increased 5.2% year on year, to ¥13,717 million. Changes in the market
environment pushed up demand, which boosted sales of instruments in the medical robotics
business. Also, sales of hematology instruments increased.
Overseas, sales of instruments, reagents and maintenance services increased in the hematology
field, as did sales of hemostasis and urinalysis reagents. These factors, plus ongoing yen
depreciation, caused overseas sales to rise 19.3% year on year, to ¥98,228 million. The overseas
sales ratio rose 1.4 percentage point, to 87.7%.
Selling, general and administrative (SG&A) expenses expanded 19.5%, to ¥36,016 million.
Behind this rise were stemming from a greater headcount and inflation-fueled rises in personnel
costs, as well as higher expenses. R&D expenses increased 3.1% year on year, to ¥7,356 million.
As a result, during the first quarter of the fiscal year ending March 31, 2025, Sysmex recorded
consolidated net sales of ¥111,946 million, up 17.4% year on year. Operating profit was up 26.1%, to¥16,743 million; profit before tax increased 29.0%, to ¥16,979 million, and profit attributable toowners of the parent rose by 28.0%, to ¥11,031 million.
Performance by segment(1) Headquarters
Sales of hemostasis and life science reagents increased, as did instrument sales in the medical
robotics business. As a result, sales in this segment rose 10.3% year on year, to ¥19,759 million.
On the profit front, SG&A expenses rose, but higher sales and an improved cost of sales ratio
pushed up segment profit (operating profit) 70.5%, to ¥10,748 million.
- 3 -(2) Americas RHQ
Sales of hematology and urinalysis reagents increased in North America, as well as Central andSouth America. In North America, sales of maintenance services in the hematology andurinalysis fields also increased. As a result, overall sales in the Americas grew 17.0% year on
year, to ¥29,785 million.
Despite the higher sales, segment profit (operating profit) fell 27.9%, to ¥1,789 million, owing
to higher SG&A expenses.
(3) EMEA RHQ
The transition to direct sales in Saudi Arabia contributed to segment performance. Sales
increased for hematology, urinalysis and hemostasis reagents. Accordingly, sales were ¥33,837
million, up 19.3% year on year.
Although SG&A expenses rose, higher sales caused segment profit (operating profit) to soar
71.0%, to ¥3,475 million.
(4) China RHQ
Sales of hematology and urinalysis reagents increased. Consequently, sales rose 16.7%, to¥19,477 million.
However, segment profit (operating profit) decreased by 19.3%, to ¥557 million, despite thehigher sales, owing to deterioration in the cost of sales ratio and an increase in SG&A expenses.
(5) Asia Pacific RHQ
Sales of hematology instruments, reagents, and maintenance services grew. This led to a 31.0%
increase in sales, to ¥9,086 million.
Segment profit (operating profit) surged 87.3%, to ¥1,668 million, due to higher sales and an
improved cost of sales ratio, although SG&A expenses grew.
2) Financial conditions analysis(1) Financial conditions
As of June 30, 2024, total assets amounted to ¥626,249 million, up ¥7,328 million from March
31, 2024. As main factors, we saw increases of ¥9,212 million in inventories, ¥1,941 million inproperty, plant and equipment, ¥2,069 million on intangible assets, and ¥1,963 in trade and otherreceivables (non-current assets), while trade and other receivables (current assets) fell ¥10,463
million.
Meanwhile, total liabilities as of June 30, 2024 were ¥177,465 million, down ¥8,558 million
from March 31, 2024. Principal decreases included trade and other payables, which was down
¥5,980 million, and accrued bonuses, which fell ¥5,641 million.
Total equity came to ¥448,784 million, up ¥15,887 million from March 31, 2024. Among
principal reasons, other components of equity rose ¥13,634 million. Equity attributable to ownersof the parent to total assets amounted to 71.5% on June 30, 2024, up 1.7 percentage points from
69.8% on March 31, 2024.
(2) Cash flows
As of June 30, 2024, cash and cash equivalents amounted to ¥76,757 million, up ¥1,249 million
from March 31, 2024.
Cash flows from various activities during the first quarter are described in more detail below.
(Cash flows from operating activities)
Net cash provided by operating activities was ¥17,966 million, up ¥6,622 million from the first
three months of the previous fiscal year. As principal factors, profit before tax provided ¥16,979
million (¥3,819 million more than in the preceding year) and a decrease in trade receivables
provided ¥17,019 million (up ¥4,557 million), while an increase in inventories used ¥6,030 million(up ¥1,242 million), and income taxes paid amounted to ¥10,321 million (down ¥2,114 million).
(Cash flows from investing activities)
Net cash used in investing activities was ¥11,132 million (up ¥839 million). Among major
factors, purchases of property, plant and equipment used ¥4,743 million (up ¥18 million), and- 4 -purchases of intangible assets used ¥5,484 million (up ¥133 million).
(Cash flows from financing activities)
Net cash used in financing activities was ¥9,010 million (down ¥1,569 million). This was mainly
due to dividends paid of ¥8,728 million (down ¥59 million).
3) Consolidated financial forecast
The Company maintains its consolidated financial forecasts, as announced on May 9, 2024.
These forecasts are based on information available as of the date of this release. Actual results
may differ materially from these forecast due to unforeseen factors and future events.
4) Operating risks
In the first quarter under review, no new operating risk emerged, and there were no materialchanges to the operating risks outlined in our financial report for the previous fiscal year.
5) Business and financial issues to be addressed
There are no significant changes to the descriptions of “Priority business and financial issues tobe addressed” in “Part I: Corporate Information, Section 2: Business Overview, 1. Management
Policy, Management Environment and Issues to be Addressed” in the financial report for theprevious fiscal year.
6) Important management contracts, etc.
No conclusions of important management contracts or decisions regarding them were madeduring the first quarter under review.

- 5 -2. Condensed quarterly consolidated financial statements and notes
1) Condensed quarterly consolidated statement of financial position(Unit: Millions of yen)
As ofMarch 31, 2024
AssetsCurrent assets
Cash and cash equivalents
Trade and other receivables
Inventories
Other short-term financial assets
Income taxes receivable
Other current assets
Total current assets
Non-current assets
Property, plant and equipment
Goodwill
Intangible assets
Investments accounted for using theequity method
Trade and other receivables
Other long-term financial assets
Asset for retirement benefits
Other non-current assets
Deferred tax assets
Total non-current assets
Total assets

－

6

－

As of
June 30, 2024

75,507
157,067
79,123
1,310
934
29,515
343,459

76,757
146,604
88,335
1,053
1,084
28,484342,319

116,693
17,22186,786

118,635
18,13888,856472

441

21,435
14,034458
4,339
14,018275,461
618,920

23,39914,132483
4,522
15,320283,929626,249

(Unit: Millions of yen)
As ofMarch 31, 2024
Liabilities and equity
Liabilities
Current liabilities
Trade and other payables
Lease liabilities
Other current financial liabilities
Income taxes payable
Provisions
Contract liabilities
Accrued expenses
Accrued bonuses
Other current liabilities
Total current liabilities
Non-current liabilities
Long-term loans payable
Lease liabilities
Other non-current financial liabilities
Liability for retirement benefits
Provisions
Other non-current liabilities
Deferred tax liabilities
Total non-current liabilities
Total liabilities
EquityEquity attributable to owners of the parent
Capital stock
Capital surplus
Retained earnings
Treasury stock
Other components of equity
Total equity attributable to owners of the parent
Non-controlling interests
Total equity
Total liabilities and equity

－

7

－

As of
June 30, 2024

33,602
8,659
1,028
12,476
1,159
16,591
21,643
12,611
10,311
118,084

27,622
9,333
1,501
8,675
1,160
17,08423,490
6,969
10,008105,847

28,60018,08076
2,239
674
10,3507,917
67,938186,023

30,60818,18071
2,442
705
11,396
8,214
71,617
177,465

14,72920,830365,985(12,315)
42,814432,045851
432,897
618,920

14,72920,831
368,288(12,318)
56,449447,979804
448,784
626,249

2) Condensed quarterly consolidated statement of income(Unit: Millions of yen)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Research and development expenses
Other operating income
Other operating expenses
Operating profit
Financial income
Financial expenses
Share of profit (loss) of associates accounted forusing the equity method
Foreign exchange gain (loss)
Profit before tax
Income taxes expenses
ProfitProfit attributable to
Owners of the parent
Non-controlling interests
ProfitThree months ended
June 30, 2023

Three months ended
June 30, 2024

95,351
44,94250,40830,148
7,131
300
151
13,277
253
404

111,946
51,90660,03936,016
7,356
234
157
16,743
213
590

(821)

(770)

856
13,160
4,598
8,561

1,384
16,9795,995
10,984

8,621
(59)
8,561

11,031(47)
10,984(Unit: Yen)

Earnings per share
Basic
Diluted

13.73
13.72

－

8

－

17.69
17.69

3) Condensed quarterly consolidated statement of comprehensive income(Unit: Millions of yen)Three months ended
June 30, 2023
ProfitOther comprehensive income
Items that will not be reclassified
subsequently to profit or loss
Net gain (loss) on financial assets
measured at fair value through othercomprehensive income
Total
Items that may be reclassified subsequently
to profit or loss
Exchange differences on translation offoreign operations
Share of other comprehensive
income of investments accounted for using
the equity method
Total
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to
Owners of the parent
Non-controlling interests
Comprehensive income

－

9

－

Three months ended
June 30, 2024

8,561

10,984

272

(736)

272

(736)

13,952

14,3534

17

13,956
14,22922,79014,37013,634
24,61822,850(59)
22,79024,665(47)
24,618

4) Condensed quarterly consolidated statement of changes in equity
Three months ended June 30, 2023
(Unit: Millions of yen)
Equity attributable to owners of the parent

As of April 1, 2023
ProfitOther comprehensive
incomeCapitalstock

Capitalsurplus14,282－

20,580 334,192
－
8,621

－

Retainedearnings

Other
Treasurycomponents
stockof equity

(314)
－

Total

18,925 387,665－
8,621

Noncontrollinginterests

Total
equity690(59)388,356
8,561

－

－

－

14,22914,2290

14,229Comprehensive income

－

－

8,621

－

14,22922,850(59)

22,790Exercise of warrants
Cash dividends
Purchase of treasury
stock
Disposal of treasury
stock
Total transactions withthe owners
As of June 30, 2023

222
－

127
－

－
(8,788)

－
－

－
－

349
(8,788)－－349(8,788)

－

－

－

(0)

－

(0)

－

(0)

－

－

－

－

－

－

－

－

222

127

(8,788)(0)－(8,439)－(8,439)20,707 334,025(315)

33,154 402,077

631

402,708

14,504Three months ended June 30, 2024
(Unit: Millions of yen)
Equity attributable to owners of the parent

As of April 1, 2024
ProfitOther comprehensive
incomeRetainedearnings

Other
Treasurycomponents
stockof equity

Capitalstock

Capitalsurplus14,729－20,830 365,985 (12,315)－－
11,031

Total

42,814 432,045－
11,031

Noncontrollinginterests

Total
equity851(47)432,897
10,984－－－－

13,634

13,634－

13,634Comprehensive income－－

11,031－

13,634

24,665(47)

24,618Exercise of warrants
Cash dividends
Purchase of treasury
stock
Disposal of treasury
stock
Total transactions withthe owners
As of June 30, 2024

－
－

－
－

－

－
－

－
(8,728)－－－(8,728)－－(8,728)

－

－

－

(2)

－

(2)

－

(2)

－

0

－

0

－

0

－

0

－

0

(8,728)(2)－(8,731)－(8,731)

56,449 447,979

804

448,784

14,72920,831 368,288 (12,318)

－

10

－

5) Condensed quarterly consolidated statement of cash flows(Unit: Millions of yen)Three months ended
June 30, 2023

Three months ended
June 30, 2024

13,1608,368

16,979
9,786

821

770

22
12,462(363)(4,787)(2,459)(1,824)(1,109)1,481

3117,019(94)(6,030)(3,637)(1,767)
(524)
1,063

4,074

1,551

(6,067)123(5,975)(646)

SubtotalInterest and dividend received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchases of property, plant and equipment
Purchases of intangible assets
Payments resulting in an increase in long-term
prepaid expenses
Purchases of investments in equity instruments
Payments into time deposits
Proceeds from withdrawal of time deposits
Other－net

23,905
133(259)(12,435)
11,34328,527
166(405)(10,321)
17,966(4,724)(5,350)(4,743)(5,484)

(111)

(258)

(69)
(581)
560
(15)

(801)
(620)
741
34

Net cash provided by (used in) investing activities
Cash flows from financing activities(10,293)(11,132)－－
349(8,788)(2,140)
(0)

2,300
(125)
－
(8,728)(2,453)(2)(10,579)(9,010)

2,980

3,426

(6,548)69,46062,911

1,249
75,50776,757

Cash flows from operating activities
Profit before tax
Depreciation and amortization
Share of loss (profit) of associates accounted for using
the equity method
Loss on retirement of non-current assets
Decrease (increase) in trade receivable
Decrease (increase) in advance payments
Decrease (increase) in inventories
Increase (decrease) in trade payable
Increase (decrease) in accounts payable–other
Increase (decrease) in contract liabilities
Increase (decrease) in accrued expenses
Decrease/increase in consumption taxes
receivable/payable
Increase (decrease) in accrued bonuses
Other－net

Proceeds from long-term loans payable
Repayments of long-term loans payable
Exercise of warrants
Dividends paid
Repayments of lease liabilities
Other－net
Net cash provided by (used in) financing activities
Effects of exchange rate changes on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the term
Cash and cash equivalents at the end of the term

－

11

－

6) Notes to the condensed quarterly consolidated financial statements
1. Key considerations on the basis for the preparation of condensed quarterly consolidated
financial statements
The condensed quarterly consolidated financial statements have been prepared in accordancewith Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated
Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordance with Article
5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, somedisclosures in International Accounting Standard No. 34 “Interim Financial Reporting” areomitted.)2. Notes related to the going concern assumption
Not applicable
3. Segment information
1) Overview of reportable segments
The Group’s reportable segments are the constituent business units of the Group forwhich separate financial data are available and that are examined on a regular basis forthe purpose of enabling the Managing Board to allocate managerial resources and evaluate
results of operations.
The Group is primarily engaged in the manufacture and sale of diagnostic instruments
and reagents. These businesses are conducted in Japan by the Company, and in theAmericas, EMEA, China and the Asia Pacific by headquarters established in those regions.
These companies formulate overarching strategies tailored to regional characteristics andconduct business activities accordingly. Headquarters and other domestic and overseas
subsidiaries are independent management units that handle production and sales for eachregion.
To date, we have organized reportable segments geographically. However, from the firstquarter under review, the Company has integrated its performance management system tofocus on managing company-specific segments in the interest of making performance
management more efficient. We have revised the reportable segments based on thismanagement approach. The five managing company-specific segments are “Headquarters,”“Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”
The companies included in these reportable segments are outlined below.
Reportablesegments
Headquarters

Americas RHQ
EMEA RHQ
China RHQ
AP RHQ

Companies included in the reportable segments
Sysmex Corporation, 13 other domestic subsidiaries, Sysmex Inostics Inc.
(United States), Oxford Gene Technology Inc. (United Kingdom), Sysmex
Partec GmbH (Germany), HYPHEN BioMed, SAS (France), Sysmex Astrego
AB (Sweden), Sysmex Korea Co., Ltd. (South Korea), nine other companies
Sysmex America, Inc., seven other subsidiaries in the Americas
Sysmex Europe SE, 27 other subsidiaries in the EMEA region
Sysmex Shanghai ltd., three other subsidiaries in China
Sysmex Asia Pacific Pte Ltd., 10 other subsidiaries in the Asia Pacific region2) Segment profit and operating results
Profit and operating results from continuing operations by reportable segment of theGroup are as follows;
Intersegment sales are determined based on market prices or costs of goods
manufactured.
Accounting policies of reporting segments are consistent with the Group’s accounting
policies indicated in the consolidated financial statements for the previous fiscal year
Segment information for the previous first quarter is based on the revised reportablesegment categories.

－

12

－

Three months ended June 30, 2023
(Unit: Millions of yen)
Reportable segment
Head- Americas
quarters
RHQ

EMEA
RHQ

China
RHQ

AP RHQ

Total

Adjustments Consolidated(Note 1)
(Note 2)

Sales
Sales toexternalcustomers
Intersegme
nt sales
Total
Segment
profit (loss)
FinancialincomeFinancialexpenses
Share ofprofit (loss) of
associates
accounted forusing theequity method
Foreignexchange gain
(loss)
Profit before
tax
Income taxes
expensesProfit17,90825,45728,36016,6896,935

95,351－

95,351

28,279

10

217

0

4

28,512(28,512)－46,18825,46728,578

16,6896,940

123,864(28,512)

95,351

6,304

2,481

2,032

690

890

12,399877

13,277

－

－

－

－

－

－

－

253

－

－

－

－

－

－

－

404

－

－

－

－

－

－

－

(821)

－

－

－

－

－

－

－

856

－

－

－

－

－

－

－

13,160

－

－

－

－

－

－

－

4,598

－

－

－

－

－

－

－

8,561

Notes:
1. Segment profit (loss) adjustments of ¥877 million include ¥825 million for the unrealized gains oninventories and ¥52 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly
consolidated statement of income.

－

13

－

Three months ended June 30, 2024
(Unit: Millions of yen)
Reportable segment
Head- Americas
quarters
RHQ

EMEA
RHQ

China
RHQ

AP RHQ

Total

Adjustments Consolidated(Note 1)
(Note 2)

Sales
Sales toexternalcustomers
Intersegme
nt sales
Total
Segment
profit (loss)
FinancialincomeFinancialexpenses
Share ofprofit (loss) of
associates
accounted forusing theequity method
Foreignexchange gain
(loss)
Profit before
tax
Income taxes
expensesProfit

19,75929,78533,837

19,4779,086

111,946－

111,946

33,036

5

151

176

10

33,380(33,380)－

52,796

29,79033,98819,654

9,097

145,326(33,380)

111,946

10,748

1,789

3,475

557

1,668

18,238(1,495)

16,743

－

－

－

－

－

－

－

213

－

－

－

－

－

－

－

590

－

－

－

－

－

－

－

(770)

－

－

－

－

－

－

－

1,384

－

－

－

－

－

－

－

16,979

－

－

－

－

－

－

－

5,995

－

－

－

－

－

－

－

10,984

Notes:
1. Segment profit (loss) adjustments of negative ¥1,495 million include negative ¥1,435 million for
the unrealized gains on inventories and negative ¥59 million for the unrealized gains on noncurrent assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly
consolidated statement of income.

－14－